Picture [LSUS] – The Business Web Portal 600x60px
Organisation › Details

AC Immune S.A. (Nasdaq: ACIU)

AC Immune SA is a Swiss-based biopharmaceutical company and a leader in Alzheimer´s disease drug development. AC Immune develops innovative therapeutics with "best in class" potential against Alzheimer´s disease and other conformational diseases along three axes: vaccines, antibodies and small molecules. The anti-Abeta antibody (crenezumab) for passive immunization is partnered with Genentech and is in Phase II development; it has been selected for the first groundbreaking Alzheimer's prevention trial. The company pursues the clinical development of the vaccines ACI-24 and ACI-35. These three clinical programs are focused on Alzheimer's disease, and are backed by a rich portfolio of preclinical compounds. A preclinical stage anti-Tau antibody is also partnered with Genentech. The therapeutic molecules are leveraged for Alzheimer´s disease diagnostic and other central nervous system and non-CNS diseases, such as Glaucoma and Down syndrome. Since its foundation in 2003, AC Immune has raised CHF 84 million from private investors. *


Period Start 2003-02-01 established
Products Industry CNS drug
  Industry 2 crenezumab
Person Person Hornstein, Jörg (AC Immune 201701– CFO before Theo Müller Group + Merck KGaA)
Region Region Lausanne VD
  Country Switzerland
  Street EPFL Innovation Park, Building B
  City 1015 Lausanne VD
  Tel +41-21-6939121
    Address record changed: 2018-07-24
Basic data Employees D: 101 to 500 (2018-12-31)
  Currency CHF
  Annual sales 7,194,000 (revenue, toal (2018) 2018-12-31)
  Profit -50,951,000 (2018-12-31)
  Cash 156,462,000 (2018-12-31)
    * Document for �About Section�: AC Immune S.A.. (1/9/14). "Press Release: AC Immune Raises CHF 20 Million and Initiates World’s First anti-pTau Vaccine Trial for Alzheimer’s Disease". Lausanne.
Record changed: 2019-09-27


Picture [LSA] – The Business Web Portal 650x89px

More documents for AC Immune S.A. (Nasdaq: ACIU)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at (European life sciences) and (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at (life sciences in German-speaking Europe) and (worldwide mass spectrometry)


Picture EBD Group BIO-Europe 2019 Partnering Report BEU2019 650x80px

» top